These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 19769698)

  • 21. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
    Paty BW
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care.
    Rutter MK; Nesto RW
    Eur Heart J; 2011 Sep; 32(18):2247-55. PubMed ID: 21705358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sugar and stroke: cerebrovascular disease and blood glucose control.
    Quinn TJ; Dawson J; Walters MR
    Cardiovasc Ther; 2011 Dec; 29(6):e31-42. PubMed ID: 20491782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.
    Zoungas S; Chalmers J; Ninomiya T; Li Q; Cooper ME; Colagiuri S; Fulcher G; de Galan BE; Harrap S; Hamet P; Heller S; MacMahon S; Marre M; Poulter N; Travert F; Patel A; Neal B; Woodward M;
    Diabetologia; 2012 Mar; 55(3):636-43. PubMed ID: 22186981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive insulin regimens: evidence for benefit.
    Bretzel RG
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S8-13. PubMed ID: 15306832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycaemic control and cardiovascular morbi-mortality: the contribution of the 2008 studies.
    Cugnet-Anceau C; Bauduceau B
    Ann Endocrinol (Paris); 2009 Mar; 70(1):48-54. PubMed ID: 19193363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes.
    Ross SA; Tildesley HD; Ashkenas J
    Curr Med Res Opin; 2011 Nov; 27 Suppl 3():13-20. PubMed ID: 21942467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Megatrials in type 2 diabetes. From excitement to frustration?
    Del Prato S
    Diabetologia; 2009 Jul; 52(7):1219-26. PubMed ID: 19373446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes.
    Yu PC; Bosnyak Z; Ceriello A
    Diabetes Res Clin Pract; 2010 Jul; 89(1):1-9. PubMed ID: 20494468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
    Macisaac RJ; Jerums G
    Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intensive glucose control in type 2 diabetes: is it harmful, needless or maybe useful in reducing cardiovascular risk?].
    Consoli A
    G Ital Cardiol (Rome); 2010 Dec; 11(12 Suppl 2):7S-11S. PubMed ID: 21361050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.
    Skyler JS; Bergenstal R; Bonow RO; Buse J; Deedwania P; Gale EA; Howard BV; Kirkman MS; Kosiborod M; Reaven P; Sherwin RS; ; ;
    Circulation; 2009 Jan; 119(2):351-7. PubMed ID: 19095622
    [No Abstract]   [Full Text] [Related]  

  • 33. [What has changed in the therapeutic strategy for type 2 diabetes mellitus?].
    Casado PP; Szymaniec J; Conthe P
    Rev Clin Esp; 2010 Sep; 210 Suppl 1():18-25. PubMed ID: 21130912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Glycaemic management in type 1 and 2 diabetes patients undergoing interventional cardiology procedures. Heart and Diabetes Working Group. Sociedad Espan˜ola de Cardiologı´a. Sociedad Espan˜ola de Diabetes].
    Alonso-García A; Moreno Gómez R; Miranda Guardiola F; Artola-Menéndez S; Lisbona-Gil A; ;
    Med Clin (Barc); 2012 Mar; 138(5):207.e1-5. PubMed ID: 22093406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Critical notes on the results of studies (ACCORD, ADVANCE, VADT) of the efficiency of intensive therapy of type 2 diabetes mellitus].
    Schwartz V
    Klin Med (Mosk); 2011; 89(3):18-20. PubMed ID: 21861397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.
    Terry T; Raravikar K; Chokrungvaranon N; Reaven PD
    Curr Cardiol Rep; 2012 Feb; 14(1):79-88. PubMed ID: 22160862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment.
    Giaccari A; Sorice G; Muscogiuri G
    Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):365-77. PubMed ID: 19428228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.
    Kitasato L; Tojo T; Hatakeyama Y; Kameda R; Hashikata T; Yamaoka-Tojo M
    Cardiovasc Diabetol; 2012 Jun; 11():79. PubMed ID: 22748110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
    Konig M; Lamos EM; Stein SA; Davis SN
    Curr Diabetes Rev; 2013 Sep; 9(5):371-81. PubMed ID: 23865412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes.
    Bailey CJ; Aschner P; Del Prato S; LaSalle J; Ji L; Matthaei S;
    Diab Vasc Dis Res; 2013 Sep; 10(5):397-409. PubMed ID: 23711582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.